The protective effects of ω-3 fatty acids on doxorubicin-induced hepatotoxicity and nephrotoxicity in rats

Tülübaş, Feti; Gürel, Ahmet; Oran, Mustafa; Topçu, Birol; Çağlar, Veli; Uygur, Emine

doi:10.1177/0748233713483203

Cited by 43 publications

(24 citation statements)

References 44 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Doxorubicin (DOX) plays an important role in the treatment of MM. It is a highly effective antitumor antibiotic used in human cancer chemotherapy; 5 however, it can cause cardiotoxicity, 6 hepatotoxicity, 7 and nephrotoxicity. 8 To reduce the side effects and improve the efficacy of drugs, research on drug carriers and synthetic nanodrugs has become the focus of modern medical research.…”

Section: Introductionmentioning

confidence: 99%

Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells

Zhao

Cui

et al. 2014

IJN

View full text Add to dashboard Cite

The purpose of this study was to evaluate the cytotoxicity of human multiple myeloma cells (RPMI-8226) treated with graphene oxide (GO), doxorubicin (DOX), and GO loaded with DOX (GO/DOX). Cell viability was determined using the Cell Counting Kit-8 assay and analyzing the cell cycle and cell apoptosis. Cells treated with GO, GO/DOX, and pure DOX for 24 hours showed a decrease in proliferation. GO/DOX significantly inhibited cell proliferation as compared with pure DOX ( P <0.01). When the effects of GO were removed, there was no observed difference between GO/DOX and pure DOX ( P >0.05). Flow cytometry analysis of untreated and GO-, DOX-, and GO/DOX-treated cells found no significant differences in the G 0 /G 1 phase ( P >0.05), while significant differences were observed in the total apoptotic rates ( P <0.05). No significant differences existed in the total apoptotic rates of GO-treated and untreated cells ( P >0.05). These findings suggest that GO caused low cytotoxicity and did not induce cell apoptosis or change the cell cycle in multiple myeloma cells. Moreover, GO did not affect the antitumor activity of DOX. In conclusion, GO would be suitable as an anticancer drug nanocarrier and used to treat hematological malignancies.

show abstract

Section: Introductionmentioning

confidence: 99%

Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells

Zhao

Cui

et al. 2014

IJN

View full text Add to dashboard Cite

show abstract

“…Interestingly, DHA is not predicted to have hepatoxicity. Therefore, a conjugation of DHA with DOX might reduce the hepatoxicity effect, as also demonstrated earlier (Tulubas et al, 2013). Tulubas and colleagues showed that the formulation of DOX with omega-3 fatty acids, including DHA, resulted in protective activity against hepatotoxicity.…”

Section: Molecular Dynamics Simulation Of Integrin Ligandmentioning

confidence: 61%

Computational Model of Doxorubicin Conjugate with Docosahexaenoic Acid and Integrin avß3 Ligand for Anticancer

2018

japs

View full text Add to dashboard Cite

Doxorubicin (DOX) is one of the most effective drugs for cancer treatment. However, the undesired side effects of DOX towards cardiotoxicity and drug resistance have raised concern about developing the safer medication. Therefore, the potency of DOX can be optimized by conjugating it with the other molecules. Integrin α v β 3 receptor which overexpressed in cancer cells can be used as a target for specific therapeutics. Fatty acids such as docosahexaenoic acid (DHA) is also known to improve the absorption of DOX in the cancer cell. Therefore, for the first time, the possibility of a conjugated drug composed of three components, i.e. DOX, integrin ligand, and DHA, is explored using the computational methods. This study aimed to propose a computational model of DOX conjugate with α v β 3 integrin ligand and DHA using structure-based design approach and to predict the pharmacokinetic properties of each component using in silico method. A peptidomimetic ligand was used as a template to develop new integrin ligand. Molecular docking was used to predict the best binding mode and energy of the ligand to enhance the selectivity of DOX conjugate. Molecular dynamics showed the stable binding of integrin ligand. In silico pharmacokinetics Key words:DHA, integrin α v β 3 , a computational model.

show abstract

“…No correlations between the levels of hepatic lipids and hepatic damageassociated diagnostic markers, such as ALT and ALP, were found in Fxr-null mice. Several studies have found that n-3 PUFAs ameliorate hepatic steatosis and hepatotoxicity caused by drug or bile duct ligation [29][30][31][32][33]. However, n-3 PUFAs are unlikely to be able to ameliorate hepatotoxicity caused by FXR deficiency.…”

Section: Discussionmentioning

confidence: 99%

Hepatic n-3/n-6 polyunsaturated fatty acid shift improves hepatic steatosis in farnesoid X receptor-null mice

et al. 2016

View full text Add to dashboard Cite

The protective effects of ω-3 fatty acids on doxorubicin-induced hepatotoxicity and nephrotoxicity in rats

Cited by 43 publications

References 44 publications

Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells

Cytotoxicity of graphene oxide and graphene oxide loaded with doxorubicin on human multiple myeloma cells

Computational Model of Doxorubicin Conjugate with Docosahexaenoic Acid and Integrin avß3 Ligand for Anticancer

Hepatic n-3/n-6 polyunsaturated fatty acid shift improves hepatic steatosis in farnesoid X receptor-null mice

Contact Info

Product

Resources

About